IP Library Granted Patent US 10,302,633
Granted Patent B2
US 10,302,633 · App. 16/042,092 · Granted May 28, 2019

Multisignal reagents for labeling analytes

Inventors: Jack Coleman (East Northport, NY); Maciej Szczepanik (Mount Sinai, NY); Richard Jin (Pennington, NJ)
Assignee: Enzo Life Sciences, Inc.
G01N33/54306C12Q1/68G01N33/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,302,633
App. No.
16/042,092
Granted
May 28, 2019
Kind
B2
Abstract

Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. In this assay, the amount of the signal or the first member of the second binding pair bound to the binding agent is inversely proportional to the analyte in the sample. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.

Claims (24)

1. A competitive binding assay composition comprising:

(a) a sample suspected of containing an analyte;

(b) a detection reagent comprising

the analyte or an analog thereof bound covalently to a first nucleic acid strand, and

a second nucleic acid strand complementary with and hybridized to the first nucleic acid strand,

wherein the second nucleic acid strand comprises more than one signal, and

wherein each signal comprises a fluorescent dye, a radioactive molecule, a chemiluminescent molecule or an enzyme; and

(c) a binding agent capable of binding to the analyte or the analog thereof of the detection reagent and to analyte contained in the sample,

wherein the analyte is cAMP, cGMP, 8-bromoadenosine 3′,5′-cyclic monophosphate, cholesterol, a hydroxycholesterol, vitamin D, 25-hydroxy vitamin D, vitamin B12, vitamin E, vitamin B1, vitamin B6, ascorbic acid, retinol, biotin, folate, legumin, salbutamol, melamine, sulfaquinoxaline, an inositol phosphate, a phosphatidyl inositol phosphate, prednisone, pregnenolone, dexamethasone, triamcinolone, fludrocortisone, dihydrotachysterol, oxandrolone, testosterone, dihydrotestosterone, nandrolone, norethindrone, medroxyprogesterone acetate, progesterone, a glucocorticoid, aldosterone, estrogen, oxytocin, androstanediol glucuronide, bilirubin, warfarin, an estrogen, methotrexate, tobramycin, acetaminophen, encainide, fluoxetine, gentamycin, an aminoglycoside, amikacin, coenzyme Q10, theophylline, phenytoin, cimetidine, disulfiram, trazodone, ethanol, halothane, phenylbutazone, azapropazone, ibuprofen, amiodarone, imipramine, miconazole, metronidazole, nifedipine, chloramphenicol, trimethoprim, a sulfonamide, rifampin, cisplatin, vinblastine, bleomycin, oxacillin, nitrofurantoin, phenobarbital, primidone, carbamazepine, metoclopramide, cholestyramine, colestipol, neomycin, sulfasalazine, digoxin, indomethacin, diltiazem, erythromycin, tetracycline, itraconazole, nicardipine, triamterene, spironolactone, chlorpromazine, a cyclosporin, nortriptyline, ethosuximide, imipramine, codeine, lorazepam, topiramate, disopyramide, levetiracetam, clobazam, oxcarbazepine, fructosamine, caffeine, methaqualone, meprobamate, fluphenazine, a barbiturate, a phenothiazine, serotonin, valproic acid, digitoxin, maprotiline, lidocaine, mexiletine, primidone, risperidone, [OH-rispiridone] paliperidone, a porphyrin, haloperidol, flecainide, tocainide, acetazolamide, a sulfonamide, verapamil, a metanephrine, an oxidized nucleotide, a mycotoxin, tetrahydrocannabinol, a cannabinoid, cocaine, LSD, an amphetamine, heroin, methadone, nicotine, cotinine, a benzodiazepine, bis(2-ethylhexyl) phthalate, bisphenol A, hydralazine, atrazine, an organochloride insecticide, an organophosphate insecticide, or a carbamate insecticide.

2. The composition of claim 1 , wherein the analyte is oxytocin, cAMP, cGMP, hydroxycholesterol, vitamin D, or 25-hydroxy vitamin D.

3. The composition of claim 2 , wherein the analyte is cAMP or vitamin D.

4. The composition of claim 1 , wherein the binding agent is an antibody or an analyte-binding fragment thereof.

5. The composition of claim 1 , wherein the binding agent is bound to a solid phase.

6. The composition of claim 5 , wherein the binding agent is an antibody or an analyte-binding fragment thereof.

7. The composition of claim 1 , wherein the detection reagent (b) consists essentially of:

the analyte or an analog thereof bound covalently to the first nucleic acid strand, and

the second nucleic acid strand complementary with and hybridized to the first nucleic acid strand.

8. The composition of claim 7 , wherein the analyte is oxytocin, cAMP, cGMP, hydroxycholesterol, vitamin D, or 25-hydroxy vitamin D.

9. The composition of claim 8 , wherein the analyte is cAMP or vitamin D.

10. The composition of claim 7 , wherein the binding agent is an antibody or an analyte-binding fragment thereof.

11. The composition of claim 8 , wherein the binding agent is bound to a solid phase.

12. The composition of claim 11 , wherein the binding agent is an antibody or an analyte-binding fragment thereof.

13. The composition of claim 1 , wherein each signal comprises a fluorescent dye or a chemiluminescent molecule.

14. The composition of claim 7 , wherein each signal comprises a fluorescent dye or a chemiluminescent molecule.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2018
From: COLEMAN, JACK; SZCZEPANIK, MACIEJ; JIN, RICHARD
To: ENZO LIFE SCIENCES, INC.
Reel/Frame 046786/0209 →
Continuity (2)
Continuation 13556304 · Jul 24, 2012
Related Publication 20180335426A1 · Nov 22, 2018